Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?

Prediction market on metaculus. [CRISPR](https://en.wikipedia.org/wiki/CRISPR_gene_editing) is genetic engineering technique which allows the genomes of living organisms to be modified. Discovered in the 2000s and seeing further development during the 2010s and 2020s, the technology has undergone medical trials for conditions as varied as cancer, diabetes, AIDS and blindness, while also being used to create gene edited food. Although numerous trials have taken place, only two conditions have had CRISPR treatments be approved by the FDA (US), MHRA (UK) or EMA (EU). Both conditions being inherited blood disorders, the same treatment was separately approved for both [sickle cell disease](https://en.wikipedia.org/wiki/Sickle_cell_disease) and [beta thalassemia](https://en.wikipedia.org/wiki/Beta_thalassemia), in which [hematopoietic stem cells](https://en.wikipedia.org/wiki/Hematopoietic_stem_cell) are removed from the body, edited using CRISPR to disrupt repression of [fetal hemoglobin](https://en.wikipedia.org/wiki/Fetal_hemoglobin) production, and then infused back into the patient.

Resolves: 1/1/2027.